Enzo Biochem, Inc.
ENZB
$0.5299
-$0.01-1.85%
OTC PK
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -17.59% | -11.30% | -4.56% | 2.72% | 204.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -17.59% | -11.30% | -4.56% | 2.72% | 204.05% |
| Cost of Revenue | -16.38% | -15.25% | -12.46% | -11.39% | 215.47% |
| Gross Profit | -19.15% | -5.89% | 7.60% | 26.51% | 192.27% |
| SG&A Expenses | -26.01% | -38.31% | -36.49% | -24.81% | 184.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.89% | -30.34% | -28.80% | -20.65% | 1,395.23% |
| Operating Income | 33.33% | 57.23% | 58.90% | 50.00% | 39.94% |
| Income Before Tax | 55.32% | 67.41% | 71.54% | 60.77% | 34.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 55.32% | 67.41% | 71.54% | 60.77% | 34.16% |
| Earnings from Discontinued Operations | -121.26% | -124.54% | -131.47% | -135.89% | 396.60% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -147.13% | -165.44% | -193.96% | -228.54% | 198.15% |
| EBIT | 33.33% | 57.23% | 58.90% | 50.00% | 39.94% |
| EBITDA | 35.70% | 60.06% | 60.77% | 49.68% | 39.23% |
| EPS Basic | -144.41% | -161.71% | -189.14% | -224.04% | 198.79% |
| Normalized Basic EPS | 57.43% | 68.94% | 72.82% | 61.95% | 36.81% |
| EPS Diluted | -145.05% | -162.61% | -190.40% | -224.37% | 198.52% |
| Normalized Diluted EPS | 57.43% | 68.94% | 72.82% | 61.95% | 36.81% |
| Average Basic Shares Outstanding | 3.38% | 3.73% | 3.74% | 3.47% | 2.88% |
| Average Diluted Shares Outstanding | 3.38% | 3.73% | 3.74% | 3.47% | 2.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |